SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001437749-19-010057
Filing Date
2019-05-15
Accepted
2019-05-15 16:06:15
Documents
1
Period of Report
2019-05-13

Document Format Files

Seq Description Document Type Size
1 FORM 4 rdgdoc.html 4  
1 FORM 4 rdgdoc.xml 4 2712
  Complete submission text file 0001437749-19-010057.txt   4171
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Issuer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
Assistant Director 1

Mailing Address 4995 BRADENTON AVE, SUITE 240 DUBLIN OH 43017-3552
Business Address
Bruck Claudine (Reporting) CIK: 0001733680 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-35076 | Film No.: 19828018